Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter study

Nik Krajnc,Harald Hegen,Gerhard Traxler,Fritz Leutmezer,Franziska Di Pauli,Barbara Kornek,Paulus Rommer,Gudrun Zulehner,Katharina Riedl, Sophie Dürauer,Angelika Bauer,Sarah Kratzwald,Sigrid Klotz,Michael Winklehner,Florian Deisenhammer,Michael Guger,Romana Höftberger,Thomas Berger,Gabriel Bsteh

Multiple Sclerosis and Related Disorders（2022）

引用 2|浏览19

暂无评分

摘要

•Treatment with S1PMs and anti-CD20 monoclonal antibodies is associated with lower seroconversion rates and antibody levels after booster vaccination.•Time to revaccination and vaccination regime (homologous vs. heterologous) do not seem to play a role in humoral immune response.•After booster vaccination, seropositivity is reached in 75.8% and 82.2% of patients on anti-CD20 monoclonal antibodies and S1PMs, respectively.•Complete B-cell depletion is a predictor of no seroconversion in patients treated with anti-CD20 monoclonal antibodies.

查看译文

关键词

Multiple sclerosis,Disease-modifying therapy,SARS-CoV-2,Vaccination,Third

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要